Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in MSI-H or dMMR Metastatic Colorectal Cancer That Has Progressed Following…

Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in MSI-H or dMMR Metastatic Colorectal Cancer That Has Progressed Following…
AstraZeneca’s Imfinzi (durvalumab) receives US FDA accelerated approval for previously treated patients with advanced bladder cancer 01 May 2017 AstraZeneca…
New Research Details Published by Merck Scientists About the Early Development of Verubecestat November 2, 2016 Merck has announced the…
November 15, 2016 Pfizer Inc. has announced that new results from the Phase 3 Oral Psoriatic Arthritis TriaL(OPAL) studies, Broaden and Beyond, will…
November 7, 2016 Pfizer Inc. has announced that it will present 20 abstracts for XELJANZ® (tofacitinib citrate) at the upcoming 2016…
October 15, 2016 Pfizer Inc. announced that three abstracts for XELJANZ® (tofacitinib citrate), being investigated in moderate to severe ulcerative colitis…
July 28, 2016 Pfizer Inc. has announced top-line results from Oral Clinical Trials for tofAcitinib in ulceratiVE colitis (OCTAVE) Sustain,…
Astellas and Seattle Genetics Present ASG-15ME and ASG-22ME Phase I Clinical Data in Metastatic Urothelial Cancer June 6, 2016 Astellas…
June 7, 2016 Pfizer Inc. has announced top-line results from Oral Psoriatic Arthritis trial (OPAL) Beyond. This is the second…
AbbVie Agrees to Buy Stemcentrx April 28, 2016 Pharmaceutical company AbbVie Inc. has agreed to acquire Stemcentrx Inc., a cancer-drug…
http://www.workingmother.com/sites/workingmother.com/files/images/2015/08/pfizer_rgb_pos_canvassed.jpg April 5, 2016 Pfizer Inc. in U.S. has announced positive results from its first phase 3 study investigation of…